Reading the competition franchise by franchise — not as a single battle
The instinctive comparison is "QDEL vs. Roche" or "QDEL vs. Abbott." That framing is misleading. Roche, Abbott, Beckman, and Siemens compete with QuidelOrtho in some segments and barely participate in others. The right question is which battles QDEL can realistically win — and which it should gracefully exit.
Vitros core lab
~50% of revenue. Outscaled 5–10× on installed base by Roche, Abbott, Beckman, Siemens. Defending the existing base, not winning new accounts.
Immunohematology
Global top-3 (~7% share) alongside Werfen (acquired Immucor) and Bio-Rad. Niche the majors haven't bothered to seriously enter. The closest QDEL has to a moat.
POC immunoassay
Sofia / QuickVue / Triage hold top-3 share in physician offices and urgent care. Fragmented market — defensible but low pricing power.
Molecular (LEX)
Discontinued Savanna in 2025; LEX VELO launches H2 2026. Cepheid has 30,000+ instruments deployed. Niche penetration is the realistic ambition, not category leadership.
Outscaled 5–10× by every major competitor
Vitros is a respected platform with genuinely differentiated dry-slide technology. It is also structurally sub-scale against an oligopoly that has been investing aggressively in clinical chemistry and immunoassay for forty years. The R&D math doesn't work; the only viable strategy is defending the installed base.
| Player | Installed analyzers | Dx R&D / yr | Menu position |
|---|---|---|---|
| Roche cobas Group leader; deepest installed base | ~70,000+ | ~$2B+ | Deepest menu (200+ assays) |
| Abbott Alinity / Architect Strong North America position | ~50,000+ | ~$2.7B (Dx + devices) | Comprehensive |
| Beckman Coulter (Danaher) DxC 500i recently launched | ~40,000+ | ~$1.5B (Danaher Dx) | Comprehensive |
| Siemens Atellica Catching up post 2017 launch | ~25,000+ | ~$2B | Comprehensive |
| QDEL Vitros Differentiated dry-slide chemistry | ~6,000–8,000 | ~$280M total co | Mid-tier menu |
R&D math doesn't close
Roche Diagnostics alone spends roughly 7× what QDEL spends on the entire company across all franchises. Product cycles are 7–10 years. New analyzer launches (cobas pro, Alinity, Atellica, DxC 500i) consolidate workflows and force vendor decisions on hospitals.
QDEL's realistic ambition is not to win new accounts. It is to extract reagent annuity from the installed base while gracefully accepting share loss as analyzers reach end-of-life over the next decade.
Installed base economics are real
Hospitals don't rip out core analyzers casually. Reagent contracts are 5–7 years. The Vitros installed base throws off recurring reagent revenue at high margins. As long as service is good and reagent menu stays current, base attrition is gradual.
Modest ongoing R&D (~$80–120M/yr against this franchise) keeps the menu acceptably current. Dry-slide chemistry remains genuinely differentiated for certain emergency / STAT use cases.
The closest QuidelOrtho has to a real moat
Transfusion medicine is structurally niche. The market is ~$2.5B globally, growing 4–5% per year. It's exactly the kind of market the majors haven't seriously prioritized — too small to move the needle for Roche or Abbott, but large enough to support 3–4 specialist players. QDEL is one of them.
| Player | Approx. share | Position / strategy |
|---|---|---|
| Werfen (acquired Immucor 2024) Spanish IVD specialist; hemostasis + IH | ~15–18% | New consolidator after Immucor deal — newly #1 |
| Bio-Rad Laboratories IH-5000 launched 2024 (CE-IVD) | ~10–12% | Strong EU presence; AI-enabled new analyzer |
| QDEL (Ortho) Vision XT launched 2024 with AI antibody detection | ~7% | Top-3 with strong North America position |
| Grifols Procleix Panther; molecular IH | ~5–6% | Donor screening and molecular focused |
| Long tail (Diagast, Quotient, regional) Smaller players, regional focus | ~50%+ | Highly fragmented globally |
Niche market the majors don't prioritize
Blood banks, transfusion services, and donor screening are specialty verticals with long sales cycles, high regulatory barriers, and customer relationships that span decades. Once a blood bank standardizes on Vision analyzers, they don't switch absent a real reason.
Roche, Abbott, and Beckman could compete here, but it would require building a dedicated transfusion medicine sales force, regulatory expertise, and reagent portfolio for a $2.5B market — bad ROI vs. their core $25B+ markets. They've consistently chosen not to.
Competitive dynamics shifted in 2024
Werfen acquired Immucor in 2024, becoming the new #1 in immunohematology and combining hemostasis with transfusion medicine on one commercial platform. That changes the competitive picture meaningfully.
QDEL now competes against a larger, better-capitalized #1 with cross-sell leverage. The Vision XT launch (2024, AI-enabled, 52% faster cross-matching) is a credible response, but holding share will require sustained R&D commitment in a franchise that doesn't get headlines.
Defensible top-3 share — but pricing power is limited
The classic Quidel franchise: Sofia for instrumented immunoassay, QuickVue for visual reads, Triage for emergency department cardiac. Real brands with real installed bases in physician offices and urgent care. Competition is fragmented — no one has dominant share — which protects QDEL but also caps pricing power.
| Player | Platform | Strength | Battleground vs. QDEL |
|---|---|---|---|
| Abbott | BinaxNOW / ID NOW | Retail / pharmacy / urgent care | Direct competitor in flu, strep, COVID |
| BD | Veritor | Physician office / urgent care | Direct competitor in flu, strep, RSV |
| Roche | cobas Liat (molecular POC) | Hospital / large clinic | Indirect — molecular shift threat |
| Cepheid (Danaher) | GeneXpert (molecular POC) | Hospital / clinic / retail | Indirect — molecular shift threat |
| QDEL | Sofia, QuickVue, Triage | Physician office, urgent care, ED | — |
| LumiraDx | LumiraDx Platform | Multi-analyte POC (struggling) | Niche; commercial issues |
Fragmented market = nobody dominates
The top 3–4 players (QDEL, Abbott, BD) each hold 15–25% share in respiratory POC. None is dominant. Switching costs are modest at the device level but high at the institutional level (training, integration, EHR connectivity).
QDEL's brands have real loyalty in physician offices. Sofia's installed base is sticky. QuickVue is the visual-read default in many urgent care chains. These positions don't evaporate; they erode slowly if at all.
The longer-term threat is platform substitution
The structural risk isn't Abbott or BD taking immunoassay share — it's the broader market moving from rapid-antigen immunoassay to POC molecular. Cepheid GeneXpert and Roche cobas Liat are both eating into the same indications.
A 5-minute molecular respiratory test at a competitive price is genuinely better than a Sofia immunoassay test for many use cases. This is why QDEL's LEX VELO bet matters defensively, not just offensively. If LEX fails, the POC immunoassay franchise erodes faster than it would in a static market.
The franchise that worries me most for long-term viability
Savanna was discontinued in June 2025 after years of development trouble. LEX (acquired for $100M) is technically promising but launches into a market where Cepheid GeneXpert alone has 30,000+ instruments deployed with multi-year contracts and trained users. Realistic ambition is niche penetration, not category leadership.
| Player | Instruments | Position |
|---|---|---|
| Abbott ID NOW Isothermal amplification; rapid POC | ~200,000+ | Ubiquitous in retail / urgent care |
| Cepheid GeneXpert (Danaher) Cartridge-based PCR; broad menu | ~30,000+ | Dominant POC molecular for hospitals |
| BioFire FilmArray (bioMérieux) Syndromic panels (resp, GI, BCID) | ~25,000+ | Premium syndromic testing leader |
| Roche cobas Liat PCR POC; expanding menu | ~10,000+ | Hospital + physician office |
| QDEL LEX VELO Acquired 2025; 6–10 min PCR | 0 | U.S. launch H2 2026 |
Late, small, and entering a saturated market
Cepheid alone has more deployed instruments than QDEL has total customers. Switching costs in molecular POC are real: hospitals validate platforms, train staff, and sign multi-year reagent contracts. Convincing a hospital to displace GeneXpert for LEX requires either materially better technology or materially better economics — preferably both.
LEX is technically credible (6–10 min vs. 20–45 min for competitors) but unproven at scale. Manufacturing, supply chain, customer service infrastructure all need to be built or bought.
5–10% niche share over 5–7 years
Realistic battleground: physician offices and urgent care that don't already have GeneXpert or Liat. Smaller hospitals where the 6-minute time-to-result has clinical workflow benefits. Specific menu wins (e.g., respiratory panels) where LEX is differentiated.
At 5–10% share of POC molecular over 5–7 years, that's $200–400M revenue. Meaningful but not transformative. The bigger value of LEX is defensive: it slows the molecular substitution threat to QDEL's POC immunoassay franchise.
Competitive scorecard across all four franchises
Each franchise rated A through F on the dimensions that drive long-term competitive viability. A clean read on where QDEL is genuinely competitive versus where it is structurally outmatched.
| Franchise | Scale | R&D fit | Customer lock-in |
Pricing power |
Growth outlook |
Overall |
|---|---|---|---|---|---|---|
| Vitros (core lab)~50% of revenue | D | D | B | C | D | C− |
| ImmunohematologyTransfusion medicine | B | B | A | A | B | A− |
| POC immunoassaySofia / QuickVue / Triage | B | B | B | C | C | B |
| Molecular (LEX)Just launching | F | C | F | D | B | D |
The portfolio is asymmetric, not uniformly weak
Casual readings of QDEL conclude "the whole company is weak vs. Roche/Abbott." That isn't right. The portfolio is genuinely two-sided: a strong franchise (immunohematology), a defensible franchise (POC), a melting franchise (Vitros), and an unbuilt franchise (molecular).
Strategic decisions should follow the franchise grades, not blanket assessments of "QDEL vs. the majors." Capital should flow to A-graded and B-graded franchises. Capital should not be burned on D and F franchises trying to compete head-on.
This is what the four-pillar turnaround playbook in the deck implicitly recognizes — but seeing it franchise by franchise sharpens the priorities.
Four franchises, four different strategies
The honest competitive read implies a clear strategic stance for each franchise. The corporate playbook isn't "compete with Roche" — it's "harvest, defend, lean in, attack selectively." Each franchise gets a different mandate, and the capital allocation across them is the real strategic decision.